YK-11 — Research Literature Summary
Class: SARM-related myostatin modulator • Page type: research-literature reference • Updated 2026-04-23
Regulatory notice — research reference only
YK-11 is a research chemical with myostatin-modulating activity and no approved human use. No peer-reviewed human clinical trials have been published. Case reports of drug-induced liver injury have been published. This page summarizes the available preclinical literature only.
Published research summary
- YK-11 is a gene-selective androgen receptor modulator with myostatin-inhibition activity reported in mouse myoblast (C2C12) studies.
- All mechanistic data are from in vitro and mouse models. There are no peer-reviewed human PK, efficacy, or safety studies.
- Hepatotoxicity has been described in published case reports involving self-administered YK-11 products.
Why this page does not publish a consumer “cycle” schedule
No human research exists. Any consumer dosing protocol would be unsupported extrapolation.
Peer-reviewed citations
Consulting a healthcare provider: This page is a reference for published research. If you are considering any health decision, consult a licensed healthcare provider. Path to Peptides does not provide medical advice.
Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.
Frequently Asked Questions
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard YK-11 research protocol uses 5mg administered morning on protocol days. Weekly Total: 7 capsules (35mg) • Cycle Duration: 8 weeks on, 4 weeks off
YK-11 is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.
Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.